TrialCancer2023

Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.

Sayeh M Lavasani et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.